Form 8-K

8-K — RenovoRx, Inc.

Accession: 0001493152-26-013653

Filed: 2026-03-30

Period: 2026-03-30

CIK: 0001574094

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001574094

2026-03-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): March 30, 2026

RENOVORX,

INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-40738

27-1448452

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

2570

W El Camino Real, Suite 320

Mountain

View, CA

94040

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (650) 284-4433

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instructions A.2. below):

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, $0.0001 par value per share

RNXT

Nasdaq

Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations

and Financial Condition.

March 30, 2026, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the

fiscal year ended December 31, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein

by reference.

Item 8.01

Other Events.

addition to announcing certain financial results, the Company’s press release provides certain updates of the Company’s clinical

trial and commercialization strategy described in such press release. The full text of the press release is attached hereto as Exhibit

99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements

and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release of RenovoRx, Inc., dated March 30, 2026

104

Cover Page Interactive

Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

RENOVORX, INC.

Date: March 30, 2026

By:

/s/ Shaun

R. Bagai

Name:

Shaun R. Bagai

Title:

Chief Executive Officer

-3-

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

RenovoRx

Reports Full Year 2025 Financial Results

and Provides Business Update

RenovoCath®

Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization

Phase

III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027

With

$13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value

Management

to Host Conference Call Today at 4:30 p.m. ET

MOUNTAIN

VIEW, Calif. – March 30, 2026 – RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq:

RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®,

a patented, FDA-cleared drug-delivery device, today announced its financial results for the full year and fourth quarter ended December

31, 2025, and is providing a business update to shareholders.

Shaun

Bagai, Chief Executive Officer of RenovoRx, commented, “2025 marked a key year as it was our first full year of RenovoCath

commercialization, generating over $1 million in revenue and reflecting strong initial physician adoption and demand in a handful of

active commercial cancer centers. We also learned many valuable lessons to finalize our go-to-market strategy that we are implementing

and building out a team to drive commercial growth in 2026 and beyond.”

Mr.

Bagai continued, “We entered 2025 having just taken our initial steps towards commercialization, with no dedicated sales team and

limited approved commercial cancer centers. We exited the year with a strong understanding of the market and a clear strategy supported

by a focused and agile sales and marketing team. Our network of active commercial cancer center clients continues to grow, resulting

in meaningful revenue generation. While we are still relatively early in the game, we believe we are beginning to unlock the broader

commercial potential for RenovoCath as a stand-alone device. Adoption across U.S. cancer centers continues to build, driven by new and

repeat orders, growing physician familiarity, and increasing procedural utilization. As of February 27, 2026, 12 U.S. cancer centers

are utilizing RenovoCath, and 21 additional centers are evaluating the device, have completed evaluation, or are preparing for activation.

These 33 centers represent a tripling of our near-term pipeline compared to the first quarter of 2025.”

“Importantly,

we established our commercial infrastructure in the fourth quarter of 2025, positioning us to scale in 2026 with a targeted focus on

high-volume cancer centers. On top of this, we have significantly strengthened our balance sheet with $10 million in gross proceeds (net

proceeds of $9.2 million) from recent financing led by new and existing institutional investors including insider participation, giving

us $13 million in cash on hand as of today. We strongly believe we now have the funding, business plan, leadership, and infrastructure

to propel execution across all of our activities as we drive towards important milestones, including breakeven operations and trial data.”

“Simultaneously,

we are advancing our pivotal Phase III TIGeR-PaC trial, which remains on track for full enrollment in the near term and with final results

anticipated next year. We recently announced the achievement of a milestone by randomizing our 100th patient in the trial.

As of March 24, 2026, 104 patients have been randomized with 72 events (deaths) observed. Our target of full enrollment by the middle

of this year would ensure a minimum of 114 patients will be randomized. Our study protocol requires us to advance a minimum of 114 patients

to randomization, so we are really in the home stretch of this trial. Moreover, our goal is to transition the 17 cancer centers that

have used RenovoCath as part of the TIGeR-PaC trial to commercial customers for RenovoCath in the second half of 2026 after completion

of TIGeR-PaC enrollment. Select TIGeR-PaC cancer centers have already begun using the TAMP™ (Trans-Arterial Micro-Perfusion)

therapy platform, enabled by the RenovoCath device, for targeted drug-delivery in the treatment of patients diagnosed with solid

tumors, giving us even more optimism for the expansion of our revenue potential” concluded Mr. Bagai.

RenovoCath

Commercialization Update

RenovoRx

achieved key milestones in the commercial launch of RenovoCath in 2025, its first full year of generating revenue. For the year ending

December 31, 2025, the Company generated $1.1 million in revenue from RenovoCath sales, driven by both new cancer centers adopting the

device and repeat orders from existing customers. This early commercial traction reflects increasing physician interest in targeted intra-arterial

drug-delivery and shows that RenovoCath is becoming widely used within clinical workflows at leading, high-volume cancer centers. The

Company also learned valuable lessons about cycle trends, activation timelines, customer preferences, and other commercial data which

it expects to apply as it seeks to grow RenovoCath revenues in 2026 and beyond.

Adoption

continued to expand across the United States, with 12 cancer centers actively utilizing RenovoCath as of early 2026 and a growing pipeline

of additional centers evaluating the device, having completed evaluation or are preparing for activation. The Company is also observing

repeat ordering patterns and increased procedural utilization among early adopters, reinforcing confidence in physician satisfaction

and the potential for recurring revenue. RenovoRx believes these trends support the long-term commercial opportunity for RenovoCath as

both a stand-alone device and a foundational platform for future drug-device combination therapies.

RenovoRx

continues to estimate that the initial total addressable market (TAM) for RenovoCath as a stand-alone device represents an approximately

$400 million peak annual U.S. sales opportunity, and ultimately a multi-billion-dollar potential as the platform expands into additional

solid tumor indications.

Clinical

Research and Scientific Programs Update

RenovoRx

continues to advance its ongoing Phase III TIGeR-PaC clinical trial evaluating intra-arterial delivery of gemcitabine (IAG) via the RenovoCath

device for the treatment of locally advanced pancreatic cancer (LAPC). The current protocol and statistical analysis plan for the TIGeR-PaC

trial requires 114 randomized patients, with 86 events (deaths) necessary to complete the final analysis. As of March 24, 2026, 104 patients

have been randomized and 72 events have occurred. RenovoRx anticipates completion of enrollment by the middle of 2026, ensuring a minimum

of 114 patients will be randomized.

During

2025, the TIGeR-PaC trial reached a key milestone with the completion of the second pre-planned interim analysis. Following its review,

the independent Data Monitoring Committee for the trial recommended that the study continue without modification, which the Company believes

is an expression of confidence in the potential for a positive outcome in the trial overall. TIGeR-PaC remains the cornerstone of RenovoRx’s

clinical development strategy and is designed to evaluate overall survival benefit with the potential to support a future New Drug Application

submission, if successful.

The

Company also continues to advance broader clinical programs by generating new data through post-marketing registry studies in solid tumors

and continued support of investigator-initiated trials (IIT) in borderline resectable and metastatic pancreatic cancer, along with exploring

physician interest in other areas. Registry and IIT studies achieve cost neutrality as capital-efficient studies providing meaningful

data that may further broaden the application for the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform which is enabled

by RenovoCath.

Fourth

Quarter 2025 and Subsequent Key Highlights

During

the fourth quarter of 2025, RenovoRx completed the initial buildout of its commercial infrastructure, including the launch of its sales

and marketing team, and continued advancing its commercialization strategy.

RenovoRx

strengthened its executive leadership team in February 2026 to support the commercial growth of RenovoCath with the appointment of Mark

Voll as Chief Financial Officer. Mr. Voll brings more than 30 years of financial leadership experience with a proven track record of

guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial

Officer for multiple publicly traded technology companies where he successfully led initiatives that scaled operations into high-growth

businesses.

February 2026, the Company established the RenovoCath Medical Advisory Board (MAB) to provide strategic clinical guidance in advancing

the TAMP therapy platform across indications of high unmet medical needs. The MAB includes leading interventional oncology experts: Nadine

Abi-Jaoudeh, MD of UCI Health, Mustafa Al-Roubaie, MD of Moffitt Cancer Center, Khashayar Farsad, MD, PhD of Oregon Health and Science

University, Ripal Gandhi, MD of Baptist Health South Florida, Paula Marie Novelli, MD of University of Pittsburgh Medical Center and

Jonathan Kessler, MD of City of Hope Comprehensive Cancer Center.

March 20, 2026, RenovoRx closed on an oversubscribed private placement of common stock and revenue milestone warrants resulting in gross

proceeds of $10 million to RenovoRx, before deducting placement agent fees and offering expenses with net proceeds of $9.2 million. The

financing was led by new and existing high-quality institutional investors, and the Company intends to use the net proceeds from the

private placement for working capital and general corporate purposes.

The

net proceeds of the private placement provide RenovoRx with a total of approximately $13 million cash and cash equivalents in hand

to drive its business towards the expected achievement of important milestones in 2026 and 2027.

Financial

Highlights for the Full Year Ended December 31, 2025

Revenue

for the year ended December 31, 2025, was $1.1 million, compared to $43,000 for the year ended December 31, 2024. Fiscal year 2025 marked

our first full year of revenue of RenovoCath and early customer adoption across U.S. cancer centers.

Cash

and cash equivalents were approximately $7.0 million as of December 31, 2025. Subsequent to year end, on March 20, 2026, the Company

strengthened its balance sheet and closed a private placement offering with gross proceeds of $10 million and net proceeds of $9.2 million.

Research

and development expenses were approximately $6.3 million for the year ended December 31, 2025, compared to approximately $6.0 million

for the same period last year. The increase was primarily attributable to continued investment in the Company’s ongoing Phase III

TIGeR-PaC clinical trial, as well as development activities related to the next generation of the RenovoCath device.

Selling,

general, and administrative expenses were approximately $7.0 million for the year ended December 31, 2025, compared to approximately

$5.0 million for the year ended December 31, 2024. The increase was primarily driven by the buildout of the Company’s commercial

infrastructure, including sales and marketing capabilities, as well as higher professional services and personnel-related costs.

Net

loss for the year ended December 31, 2025, was approximately $11.2 million, compared to approximately $8.8 million for the prior

year.

of common stock outstanding as of March 23, 2026 was 45,052,706.

Conference

Call Details

Event:

RenovoRx Fourth Quarter

& Full Year 2025 Financial Results and Business Highlights Call

Date:

Monday, March 30, 2026

Time:

4:30 p.m. ET

Live Call:

1-877-407-4018 (U.S. Toll

Free) or 1-201-689-8471 (International)

Webcast:

https://ir.renovorx.com/news-events/ir-calendar-events

For

interested individuals unable to join the conference call, a link to the recording will be available on RenovoRx’s Investor

Relations website, and a dial-in replay will be available until April 13, 2026 and can be accessed by dialing 1-844-512-2921 (U.S.

Toll Free) or 1-412-317-6671 (International) and entering replay pin number 13758677.

question and answer session will occur at the end of the call, and a link to the recording of this presentation will be available on

RenovoRx’s Investor Relations website after the event.

RenovoRx,

Inc.

Selected

Balance Sheet Data

(in

thousands, except for share and per share amount)

December 31,

2025

2024

Cash and cash equivalents

$ 7,024

$ 7,154

Total assets

$ 8,095

$ 8,118

Total liabilities

$ 2,673

$ 3,640

Total stockholders’ equity

5,422

4,478

Total liabilities and stockholders’ equity

$ 8,095

$ 8,118

RenovoRx,

Inc.

Selected

Statement of Operations Data

(in

thousands, except for share and per share amount)

Year Ended

December 31,

2025

2024

Revenues

$ 1,123

$ 43

Cost of revenues

327

Gross profit

$ 796

$ 43

Operating expenses:

Research and development

6,269

6,025

Selling, general and administrative

7,037

4,988

Total Operating expenses

13,306

11,013

Loss from operations

(12,510 )

(10,970 )

Change in fair value of warrant liability

915

1,772

Interest and dividend income, net

427

384

Total other income, net

1,342

2,156

Net loss

$ (11,168 )

$ (8,814 )

Net loss per share, basic and diluted

$ (0.32 )

$ (0.40 )

Weighted-average shares of common stock outstanding - basic and diluted

35,333,127

22,271,163

About

RenovoCath

Based

on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic

and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion

in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding

our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.

About

RenovoRx, Inc.

RenovoRx,

Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®,

a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s

patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the

arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic

intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and

improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted

delivery of diagnostic and therapeutic agents.

RenovoRx

is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In its first full year of commercial

efforts, RenovoRx generated approximately $1.1 million in RenovoCath sales and learned valuable lessons that will help drive growth in

2026 and beyond. Several customers have already initiated repeat orders and the number of medical institutions initiating new RenovoCath

orders is expanding, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated

demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical

device commercial partner.

RenovoRx

is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath,

known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug

division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes

RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications

including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

The

IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved

for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides

seven years of market exclusivity upon new drug application approval by the FDA.

For

more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary

Note Regarding Forward-Looking Statements

This

press release, the conference call described herein, and statements of the Company’s management made in connection therewith contain

forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange

Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, (ii) the potential for our product

candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize

our RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking

statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature,

are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These

may include estimates, projections, and statements relating to our research and development plans, intellectual property development,

clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on

current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ

materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using

words such as “may,” “expected,” “plans,” “aims,” “anticipates,” “believes,”

“forecasts,” “estimates,” “intends,” “potential,” “milestone” and “towards”

or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans, or intentions,

although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties

and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including,

among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue

generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand

or raise additional funding; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses)

of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive

of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our

product candidate; (v) that the applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical

development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for

our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy

platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete,

clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer

from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential

of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates

for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential

benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, and needs for additional

financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future

operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to

identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product

candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy

platform, product candidates, and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their

ability to perform adequately; (xx) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xxi) developments

relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing

and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with

the Securities and Exchange Commission.

Forward-looking

statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking

statements to reflect subsequent events or circumstances, except as required by law.

Contact:

KCSA

Strategic Communications

Valter

Pinto or Jack Perkins

T:212-896-1254

RenovoRX@KCSA.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (6919 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Mar. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 30, 2026

Entity File Number

001-40738

Entity Registrant Name

RENOVORX,

INC.

Entity Central Index Key

0001574094

Entity Tax Identification Number

27-1448452

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2570

W El Camino Real

Entity Address, Address Line Two

Suite 320

Entity Address, City or Town

Mountain

View

Entity Address, State or Province

Entity Address, Postal Zip Code

94040

City Area Code

(650)

Local Phone Number

284-4433

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value per share

Trading Symbol

RNXT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration